This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
Zumutor Biologics Inc.
National Cancer Institute (NCI)
Astex Pharmaceuticals, Inc.
OHSU Knight Cancer Institute
Sierra Oncology LLC - a GSK company
Celgene
AstraZeneca
Celgene
University of Wisconsin, Madison
AbbVie
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Memorial Sloan Kettering Cancer Center
Rutgers, The State University of New Jersey
Valerio Therapeutics
National Cancer Institute (NCI)
University of Chicago
Tesaro, Inc.
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Novacea